Published on 3 Apr 2018
Clive Dix, chief executive of C4X Discovery Holdings plc (LON:C4XD),
discusses with Proactive's Andrew Scott their licensing deal with FTSE
250-listed Indivior for its addiction behaviour suppressant, C4X3256.
http://www.4-traders.com/C4X-DISCOVERY-HOLDINGS-PL-18426389/
http://www.4-traders.com/C4X-DISCOVERY-HOLDINGS-PL-18426389/
It is the first major partnership for C4X, which will receive US$10mln
up front and a further US$284mln dependent on how successful the drug
proves.
No comments:
Post a Comment